Poly-Substance Abuse in Office-Based Buprenorphine Treatment


January 8, 2013

Poly-Substance Abuse in Office-Based Buprenorphine Treatment

Jeffrey Baxter, M.D., Presenter
Assistant Professor, Department of Family Medicine and Community Health
University of Massachusetts Medical School

John A. Renner, Jr., M.D., Discussant
Professor, Boston University
Director, Addiction Psychiatry Residency Training
Boston University and VA Boston Healthcare System

Opioid agonist treatment with buprenorphine has been shown to be effective for suppressing opioid withdrawal symptoms, reducing opioid abuse and retaining patients in addiction treatment. Many patients with opioid addiction also abuse other substances, such as alcohol, cocaine, benzodiazepines and prescription stimulants. Buprenorphine prescribers must address the abuse of these other non-opioid substances when they occur in the context of buprenorphine treatment.

The goal of this session is to explore, through a case discussion, clinical responses to the abuse of non-opioid substances for patients in buprenorphine treatment. Drs. Baxter and Renner will:

** Discuss strategies for addressing the abuse of non-opioid substances both at the time of admission to buprenorphine treatment and during ongoing buprenorphine maintenance;

** Describe options for enhancing treatment by utilizing specialty addiction treatment modalities; and

** Address decision making around discontinuing buprenorphine treatment and procedures for referring patients to more intensive levels of care.

Please click here to view the presentation slides.